Two Sigma Investments
IMDX

Two Sigma Investments’s Insight Molecular Diagnostics IMDX Stock Holding History

Two Sigma Investments’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-8,115
Closed -$352K – 3828
2021
Q4 		$352K Sell
8,115
-19,551
-71% -$1.12M ﹤0.01% 3532
2021
Q3 		$1.97M Buy
27,666
+810
+3% +$74.5K ﹤0.01% 2006
2021
Q2 		$3.08M Buy
26,856
+5,779
+27% +$564K 0.01% 1533
2021
Q1 		$2.19M Buy
+21,077
New +$2M 0.01% 1638
2020
Q3 		– Sell
-9,482
Closed -$362K – 3422
2020
Q2 		$362K Buy
9,482
+8,832
+1,359% +$456K ﹤0.01% 2245
2020
Q1 		$32K Buy
+650
New +$31.9K ﹤0.01% 2955
2019
Q4 		– Sell
-1,045
Closed -$44K – 3893
2019
Q3 		$44K Buy
+1,045
New +$41.1K ﹤0.01% 3356

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Two Sigma Investments's IMDX Position: Q1 2022 in Review

Two Sigma Investments sold out of Insight Molecular Diagnostics (IMDX) in Q1 2022, closing a stake of 8,115 shares — an estimated $352K sold.

Two Sigma Investments first reported a position in IMDX in Q3 2019 and held it in 7 quarters. The position peaked at $3.08M in Q2 2021. 86 funds tracked by Wall St. Rank hold IMDX as of Q1 2022.

  • Two Sigma Investments reported no remaining Insight Molecular Diagnostics position as of Q1 2022 after selling out during the quarter.
  • Two Sigma Investments sold 8,115 Insight Molecular Diagnostics shares in Q1 2022, an estimated $352K.
  • Two Sigma Investments first reported a position in Insight Molecular Diagnostics in Q3 2019 and held it in 7 quarters.
  • Two Sigma Investments's Insight Molecular Diagnostics position peaked at $3.08M in Q2 2021.
  • 86 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2022.

Based on Two Sigma Investments's 13F filing for Q1 2022, filed 16 May 2022.